# Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study

> **NCT02316470** · PHASE2 · COMPLETED · sponsor: **Valneva Austria GmbH** · enrollment: 500 (actual)

## Conditions studied

- Clostridium Difficile

## Interventions

- **BIOLOGICAL:** VLA84
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02316470
- **Lead sponsor:** Valneva Austria GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-05
- **Final completion:** 2015-10
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2017-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02316470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02316470, "Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02316470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*